March 11, 2021
Positive data continue to emerge from Phase II clinical trials in advanced prostate cancer of a synergistic drug combination identified by the Yaffe Lab. Fine-tuning the dosing schedule more than doubled the percentage of patients whose cancer stabilized or responded positively to treatment. Ongoing biomarker research in the Yaffe Lab has revealed genetic mutations that may help clinicians predict treatment response to the combination and support efficient design of future trials. This trial and related research have been funded in part by the Bridge Project and the MIT Center for Precision Cancer Medicine.